Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Beyond EGFR TKI in EGFR-mutant non-small cell lung cancer patients: main challenges still to be overcome.

Cancer treatment reviews - 1 Jul 2014

Remon J, Morán T, Reguart N, Majem M, Carcereny E, Lianes P

Abstract excerpt

First line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) is the standard treatment in advanced EGFR-mutant Non Small Cell Lung Cancer (NSCLC) patients, with an improvement in response rate, progression free survival, and quality of life compared with upfront chemotherapy. However, in the real world, EGFR mutation results often return positive once chemotherapy has been started. Different...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Clinical Trials, Phase III as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Drug Administration Schedule

Share to Molecular Targeted Therapy

Share to Protein-Tyrosine Kinases

Share to Quality of Life

Share to Randomized Controlled Trials as Topic

Source

Identifiers

PMID: 24759598
DOI: 10.1016/j.ctrv.2014.03.006

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Beyond EGFR TKI in EGFR-mutant non-small cell lung cancer patients: main challenges still to be overcome.PMID 24759598Read ↗

First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?Semantic proximity Read ↗

EGFR-TKIs in non-small-cell lung cancer: focus on clinical pharmacology and mechanisms of resistance.Semantic proximity Read ↗

Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?Semantic proximity Read ↗

Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer.Semantic proximity Read ↗

Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures.Semantic proximity Read ↗

Emerging treatment for advanced lung cancer with EGFR mutation.Semantic proximity Read ↗

Overview of the multifaceted resistances toward EGFR-TKIs and new chemotherapeutic strategies in non-small cell lung cancer.Semantic proximity Read ↗

A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives.Semantic proximity Read ↗

Epidermal growth factor receptor-targeted therapy for the treatment of non-small cell lung cancer: a review of phase II and III trials.Semantic proximity Read ↗

Strategies to Improve Outcomes of Patients with EGRF-Mutant Non-Small Cell Lung Cancer: Review of the Literature.Semantic proximity Read ↗

[Optimal therapeutic strategy for non-small cell lung cancer with mutated epidermal growth factor receptor].Semantic proximity Read ↗

Hype or hope - Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.